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HISTORY
The W.M. Keck Foundation Biotech-
nology Resource Laboratory
(http://keck.med.yale.edu/) began in 1980,
when its precursor (the Protein Chemistry
Facility, PCF†) was founded by Drs. Ken-
neth Williams and William Konigsberg in
the Department of Molecular Biophysics &
Biochemistry.Today,theKeckLabprovides
morethan175state-of-the-artgenomic,pro-
teomic, biostatistical, bioinformatics, and
high performance computing technologies
to hundreds ofYale and non-Yale investiga-
tors whose research programs otherwise
may not benefit from the highly sophisti-
cated and expensive instrumentation upon
whichbiologicalandbiomedicalresearchis
increasingly dependent.
ThegenesisoftheKeckLabarosefrom
the two years (1978-9) needed by Williams
and other staff to sequence the 301 amino
acidsofasingle-strandedDNAbindingpro-
tein(gp32)frombacteriophageT4[1].Dur-
ing this time, Williams was a postdoctoral
associate with Konigsberg, and his research
required a complete sequence of gp32 for
continuedprogress.Althoughaneighboring
groupofinvestigatorshadacquiredanauto-
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RR024139.matedpeptidesequencerviaaNationalInsti-
tutes of Health (NIH) Program Project grant,
littletimewasavailableonthisinstrumentfor
the gp32 project. Instead, most of the gp32
sequence had to be determined by manual
Edman degradation, with much of this work
carriedoutbyastaffmember,MaryLoPresti.
Each15residuetrypticpeptiderequiredthree
weekstogeneratethe15resultingaminoacid
derivatives that would then be identified by
reversephase(RP)HPLC.Theexperienceof
spending two years manually sequencing
peptidesthatcouldhavebeensequenced“au-
tomatically” on a nearby instrument that op-
erated unattended and continuously once the
sampleand reagents were loadedforever im-
bued in Williams the desire to bring biotech-
nology instrumentation within equal and
sufficient access of allYale investigators.
While virtually every university now
has one or more biotechnology core labora-
tories, there were few such cores in 1980,
with the Keck Lab being among the first and
developing into one of the largest. The PCF
began in a small section of Konigsberg’s
laboratory. Initially, the PCF was equipped
with a Beckman 121M Amino Acid Ana-
lyzer with the apt serial number “007,”
which contained seemingly endless miles of
capillary tubing that often led “nowhere” —
as the instrument had been extensively “cus-
tomized.” The first two PCF staff members
were LoPresti (1980) and Kathy Stone
(1982), who both still work in the Keck
MS/Proteomics Resource. Since 1980, the
Keck Lab has grown to 12 Resources (Table
1), each with its own director and budget.
WhentheKeckLabneedstoexpandinto
a new area of biotechnology, it does so to the
maximalpossibleextentbybringingtogether
and building on existing Yale expertise and
infrastructure. Rather than start its own
oligonucleotide synthesis resource, the Keck
Labmergedin1988withtheOligonucleotide
Synthesis Core in Genetics, directed by John
Flory, PhD, who continues to direct this re-
source and is one of two associate directors
of the Keck Lab. In 1998, the Keck Mass
Spectrometry (MS) Resource, founded in
1993 by Kathy Stone, merged with the Yale
Cancer Center MS Shared Resource directed
by Walter McMurray, PhD. The resulting
YCC/Keck Proteomics Resource brought a
wealth of complementary MS experience to
bear on biological and biomedical research.
McMurray’s experience included analysis of
lunar samples from theApollo 11 mission.
TECHNOLOGIES PROVIDED
Survey suggests an unusually wide
range of services
TheKeckLaboratoryhelpsinvestigators
compete for grants by providing access to
state-of-the-art biotechnologies, including
many that are seldom offered by academic
corelaboratories,whichincreasesthecompet-
itiveness of grant applications proposing use
of these technologies. According to a 2006
proteomics survey by Keck staff of 25 core
laboratories at institutions similar to Yale or
having large biotechnology cores, the Keck
Laboratory provides competitive service
charges and a very wide range of technolo-
gies.Ofthe20majorproteomics/MSservices
surveyed (all of which are available from the
Keck Lab), the average non-Yale academic
core lab provided four services — with a
range of 0 to 12. Besides the Keck Lab, no
othercoresurveyedofferedSEC/LSdetermi-
nation of the native MW of proteins or FT-
ICRMS;onlytwoothercoresofferediTRAQ
proteinprofiling;andonlytwoothercoresof-
fered DIGE profiling with MALDI-MS/MS
protein identification. The median service
chargeforthe20proteomicstechnologiessur-
veyed was $128 for the Keck Lab as com-
pared to $139 for all 25 core labs; only the
Keck Lab offered all 20 services surveyed.
While the Keck Laboratory was built on
the foundation provided by established pro-
teomics technologies (e.g., amino acid analy-
sis), it expanded to include established
genomics technologies (e.g., oligo synthesis)
andseveralemergingtechnologies.Table1and
the following sections provide brief descrip-
tionsoftechnologiesavailablefromthe12Re-
sourcesthataretheKeckLab.Table2liststhe
major instruments in each Resource.Alisting
ofafewrecentpublicationsillustratingtheuse
of selected Keck technologies in research is at
196 Williams: Keck Labhttp://keck.med.yale.edu/pdfs/Publications_usi
ng_Keck_technologies_032808.pdf.
ESTABLISHED PROTEOMICS
TECHNOLOGIES
Amino Acid Analysis Resource
The first Keck Resource established
uses cation exchange HPLC, which can tol-
erate reasonable amounts of many non-
volatile salts and detergents, and external
calibration to quantify amino acids in acid
hydrolysates of cell/tissue extracts, proteins,
and peptides, as well as in similar unhy-
drolyzed samples. Separated amino acids are
quantified with post-column ninhydrin de-
rivatization for detection at 570 nm and 440
nm.Amino acid analysis of hydrolyzed sam-
ples determines protein/peptide concentra-
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Table 1: Brief Overview of Resources within the Keck Laboratory
Resource
Amino Acid Analysis
(1980)a
Bioinformatics
(2008)
Biostatistics
(2002)
Biophysics
(1999)
DNA Sequencing
(1989)
High Performance
Computing (HPC)
(2005)
Mass Spectrometry
(MS)/Proteomics
(1993/1980)
Microarray
(1999)
Oligo Synthesis
(1988)
Peptide Synthesis:
Large Scale
(1986)
Peptide Synthesis:
Small Scale
(1994)
Protein Sequencing
(1980)
Major Technologies
Hydrolysis, amino acid analysis of peptides & proteins
Free or low cost 24/7 access to software for sequence, micro-
array, genotyping, MS, & pathway data analysis; pipelining
data processing; and molecular modeling using Lasergene,
Gene Construction Kit, Genespring GX, Partek Genomics
Suite, Gene-Spring GT, HelixTree, Ingenuity Pathway, Meta-
Core, Sybyl, Mol-CAD, Pipeline Pilot, VIBE, GPMAW.
Statistical analysis of Affymetrix, Illumina, and in-house
spotted expression & SNP arrays as well as of MALDI-MS,
iTRAQ, ICAT, DIGE, peptide disease biomarker discovery,
and other proteomics data using open source and commer-
cial software and in-house developed programs.
Microcalorimetry, HPLC SEC/laser light scattering (LS), dy-
namic LS, stopped flow absorption/fluorescence kinetic
analysis, surface plasmon resonance, & spectrofluorometry
Single tube & 96 well sequencing; primer walking, se-
quence assembly & editing, fragment analysis; high
throughput (Solexa) sequencing available through Microar-
ray Resource
Two PhD computer scientists support users of Yale HPC
Centers by optimizing, parallelizing, and de novo writing of
codes and by use of: message passing (MPI), Linda-like par-
allel languages, batch queuing (PBS) & other methodologies.
Peptide, protein, oligo, small molecule MS; protein identifi-
cation (ID) by MS/MS peptide sequencing; FT-ICR MS
exact mass; ID of posttranslational modifications; LC/MS;
differential 2D gel electrophoresis (DIGE), 8-plex Multi-
plexed Isobaric Tagging Technology (iTRAQ), & LC-MS dis-
ease biomarker discovery protein profiling.
Custom glass slide microarrays printed with oligos, cDNAs,
& proteins (e.g., Ab and cell lysates). Affymetrix, Illumina, &
Nimblegen gene expression profiling & SNP genotyping.
High-throughput Solexa DNA sequencing & 384 well plate
quantitative PCR
DNA oligo synthesis (40nmol, 200 nmol & 1.0 micromole
scales), a wide range of modified DNA oligos can be syn-
thesized – will incorporate most commercially available and
some custom synthesized modified amidites; RNA oligo
synthesis (1.0 micromole); gel purification.
Peptides are made using tBOC chemistry at the 0.5 mmol
scale, yields for normal peptides <40 residues are "guaran-
teed" at >50 mg & >90% purity. Many different unusual
amino acids may be incorporated during synthesis
Peptides made with Fmoc chemistry at 25, 50 &100 ﾵmol
scales with or without RP-HPLC purification. Avg. yield from
100 ﾵmol synthesis of 5-25mer is 20-200 mg crude,1-10
mg purified. Many different unusual amino acids may be in-
corporated during synthesis.
Edman (chemical) sequencing of proteins/peptides blotted
onto PVDF membranes (less than 15 mm2) or submitted in
<0.1 ml volatile solvent. Max. sample load is <1 nmol, with
best results obtained on 10-100 pmol sample.
Notes
Limit of detection for determining [protein] is about 0.5 ﾵg or 50-
200 pmol for individual amino acids, best approach for quantify-
ing [peptide] & [protein].
Two PhD staff provide training on software use; fee-based bioin-
formatics consultation services; and collaborate on projects re-
quiring longer-term commitment of time and effort, the latter is
often funded by an appropriate % effort charged to a grant.
Developed novel statistical methods to analyze microarray gene ex-
pression data using pathway-based tests [2]; SNP association data;
and a customized, Random Forest disease biomarker discovery al-
gorithm for analysis of MALDI-MS data acquired on sera [3,4]
Quantitative analysis (e.g., kinetics, stoichiometry, thermodynamics
& binding affinities) of interactions between biomolecules; many in-
struments available for direct use by investigators with training and
support for projects’ design, implementation, & data interpretation.
Avg read length is 650 bp, but can be as high as 700-750 bp. CY
2007 throughput =206,387 seq. runs. Sequence 6-10 x 96-well
plates/day with 24-hour turnaround and some same day sequencing.
The Yale clusters & other HPC instrumentation are used to
carry out many analyses: large scale BLAST comparisons,
Pseudogene searches, Electron microscopy image processing,
Gaussian evaluation, molecular dynamics simulations of pro-
teins, primer design for gene chips, & use of Matlab, Perl,
Python and R to support distributed computing.
DIGE uses Cy-2, Cy-3, Cy-5 in vitro labeling of control vs experi-
mental protein extracts prior to mixing the samples and subjecting
to 2D PAGE. The dynamic range of 104 and ability to quantify ex-
pression of >1,500 protein spots/2D gel surpasses that of other
profiling technologies. DIGE and iTRAQ are the two most powerful
and usually quite complementary protein profiling technologies.
Custom & generic oligo & cDNA microarrays printed for human,
mouse, rat, Arabidopsis, Drosophila, and other species. Custom
protein array printing. Full service training & project support.
>130 publications acknowledging Microarray Resource support.
CY 2007 throughput was 31,980 chargeable oligos. Current
charge for a 40 nmol 50-mer is $28 as compared to $48 in
1998. Turn-around for normal, unpurified DNA oligos is typically
<24 hours for <60-mers.
Peptides usually can be made up to 40 residues and often, de-
pending on sequence, up to 70 residues. All peptides that can
be purified are chromatographed on a preparative C-18 or C-4
RP-HPLC.
Service is designed for 7-30 residue peptides. Since the diffi-
culty in synthesizing peptides is length, composition, and se-
quence dependent; some peptides within this range will be
difficult to synthesize. Conversely, many peptides can be syn-
thesized that are >30 residues.
Limit of detection is 50 fmol of an individual amino acid. In gen-
eral, 1 to 10 pmol is sufficient to sequence from 5 to >25
residues, with the quality of data and length of sequence that
can be assigned increasing with the amount of sample.
a(Founding year) for the individual Keck Resource.tions, amino acid compositions, percent dry
weight of synthetic peptides, and the percent
incorporation of modified amino acids into
proteins (e.g., seleno-Met for X-ray crystal-
lography). Unhydrolyzed samples are ana-
lyzed to determine the background of “free”
amino acids and the extent of depletion of
individual amino acids from cell media.The
recommended amount of protein is 3-5 ﾵg
for an amino acid composition or concentra-
tion with about (ﾱ10 percent) accuracy.
Since amino acid analysis is an accurate
technology for determining protein concen-
trations, it is often used prior to many pro-
tein profiling approaches where it is helpful
to match the concentrations of the control
vs. experimental samples.
Protein Sequencing Resource
N-terminal, Edman protein/peptide se-
quencingchemicallyremovesasingleamino
acid/47 min instrument cycle from a peptide
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Table 2: Major Instruments and Instrument Systems in the Keck Laboratory
Amino Acid Analysis
Biophysics
DNA Sequencing
Biomedical High
Performance
Computing Center
ITS
Mass Spectrometry
& Proteomics
Microarray
Oligo Synthesis
Peptide Synthesis:
Large Scale
Peptide Synthesis:
Small Scale
Protein Sequencing
Resource Instrument Systems
Amino Acid Analyzer: Ion Exchange
Fluorescence Polarization System
Spectrofluorometer
Stopped Flow Absorption/Fluorescence Kinetics
HPLC SEC/Laser Light Scattering System (SEC/LS)
Dynamic Light Scattering Detector (DLS)
Isothermal Microcalorimeter (ITC)
Surface Plasmon Resonance Sensor (SPR)
DNA Sequencer: 96 Capillary
Biorobot
Biorobot
Bulldogi Compute Cluster (680 cores = CPU, 170 nodes)
Bulldogc Compute Cluster (260 cores = CPU, 130 nodes)
30 TB SAN Storage Device
31 TB Disk Array Storage Device
SMP server (8 cores = CPU)
Scalemp SMP (48 cores = CPU)
10 TB Lustre Filesystem Storage
Compute Cluster (Dual CPUs, 5 nodes)
MALDI TOF/TOF MS
LC-Electrospray/ Quadrupole/TOF MS
LC-Electrospray/ Quadrupole/TOF MS
LC-Electrospray/ Quadrupole/TOF MS
LC-Electrospray/ Quadrupole/TOF MS
LC-Electrospray/LTQ-Orbitrap Mass Spectrometer
LC-Electrospray/APCI Qtrap
LC-Electrospray FT-ICR MS
LC/Sample Prep Workstation
LC/MALDI-MS Sample Spotter
BioRobot
HPLC Systems: Analytical
2D Chromatofocussing/RP HPLC Protein Profiling System
Differential Fluorescence 2D Gel Protein Profiling System
96 Plate Well Scanner
Hybridization Oven
Fluidics Station
Scanner
Micro-electrophoresis Bioanalyzer
BeadArray Microarray System
BeadArray Scanner with Autoloader
TCAN Robot
Sequenom MassArray
Genome Analyzer sequencer
Maui Hyb ovens
Biorobot
Biorobot
Biorobot
GeneMachines Microarrayer
Glass Slide Microarray Scanner/2 Fluor Capability
Glass Slide Microarray Scanner/16 Fluor Capability
Resonance Light Scattering Microarray Reader
Gel Imaging/Dcumentation System
Spectrophotometer
Quantitative PCR Machine
Oligo Synthesizer: 4 Column/Parallel
Oligo Synthesizer: 96 Well Based/Parallel
Oligo Synthesizer: 48 Column/Parallel
Capillary Electrophoresis System
Spectrophotometer
Microplate Absorbance Reader
tBoc Peptide Synthesizer: 3 Vessel/Sequential
HPLC Systems: Preparative
HPLC Systems: Analytical
MALDI/TOF Mass Spectrometer
Multiple Peptide Synthesizer: 12 Vessel/Parallel
HPLC Systems: Preparative
HPLC Systems: Analytical
Protein/Peptide Sequencer
Hitachi L8900A-PH
PanVera BEACON System
SLM 8000C
Applied Photophysics Limited SX.18MV
Waters' HPLC/Wyatt DAWN LS & QELS Dynamic LS & Optilab rEX RI Detectors
DynaPro 800 Proterion Corp.
MicroCal VP-ITC
GE HealthCare/BiaCore 1000
Applied Biosystems 3730XL
Tecan Genesis RSP 150
Beckman Coulter Biomek NX MC
Dell PowerEdge 1955 blades
Dell PowerEdge 1855 blades
EMC CX-500
Satabeast
Dell PowerEdge 6850
F1240
N/A
Dell PowerEdge 2850 (Master) & 1850 (Compute) Nodes
ABI 4700 & 4800
Waters capLC/Micromass Q-Tof API
Waters cap LC/Micromass Q-Tof Micro
Dionex Ultimate Nano HPLC/ABI-Star XL
Dionex Ultimate Nano HPLC/ABI Q-Star Elite
Waters nano-Acquity UPLC/Thermo Fisher LTQ-Orbitrap XL
Waters nano-Acquity UPLC/ABI 4000 Qtrap
Bruker Daltonics 9.4T Apex Qe FT-ICR
Vision Work Station
Dionex LC-MALDI Sample Collection Module
Micromass MASSPrep
Hewlett Packard 1090 & 1100
Beckman Coulter Proteome Lab PF2D Protein Fractionation System
Amersham Biosci. Typhoon 9410 Scanner
Amersham Biosci. ETTAN Gel Spot Picker
Amersham Biosci. ETTAN TM Gel Digester
Meso Scale Discovery SECTPR Series
Affymetrix 640
Affymetrix 400
Affymetrix 7G
Agilent 2100
Illumina
Illumina
Illumina
Sequenom
Illumina
Maui
Qiagen 9600
Robbins Hydra-96 Microdispenser with Twister H Plate Stacker
Matrix Technologies Tango Liquid Dispenser
Omnigrid
Axon GenePix 4000A
Perkin Elmer ScanArray 5000
Qiagen HiLight Reader
BioRad Gel Doc
Hitachi GeneSpec II
Applied Biosystems 7900
Applied Biosystems 394
GeneMachines Polyplex
Applied Biosystems 3900 High Throughput DNA Synthesizer
Beckman P/ACE MDQ
Perkin Elmer Lambda 3
SpectraMax Plus
Applied Biosystems 430A
Waters 3000
Waters 510 & 6000
Micromass M@LDI-L/R
Rainin Symphony
Waters' 600E
Varian Prostar, HP1100, Rainin Dynamax
Applied Biosystems Procise 494 cLC
Description Manufacturer Qty
1
1
1
1
1
1
1
1
3
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
2
3
1
1
2
2
2
1
1
3
2
1
1
2
1
1
1
1
1
1
10
1
3
3
1
1
3
2
2
1
3
3
3
1
Total instrument systems 107or protein. The resulting phenylthiohydan-
toin derivative of each amino acid derivative
isidentifiedandquantifiedbyon-lineHPLC.
We believe the Applied Biosystems (AB)
Procise 494 cLC instrument used is the most
sensitive,commerciallyavailableinstrument.
Common uses of this technology are to con-
firm the N-termini of recombinant proteins,
identify limited proteolytic cleavage sites,
find sites of post-translational modification
(e.g., radiochemical sequencing with [32P]-
peptides)orofcross-linking(e.g.,toDNAor
RNA), and to obtain peptide sequences from
novel proteins to design oligo-primers for
DNA sequencing of the corresponding
genes. While trypsin digestion followed by
MS/MS analysis of the resulting peptides is
the method of choice for protein identifica-
tion, Edman sequencing often is the best ap-
proach for determining N-terminal
sequences of peptides/proteins that are >
3,000 Da (the approximate upper limit for
“standard” MS/MS-based peptide sequenc-
ing). Exceptions are intact proteins from
higher eukaryotes such as mammals where
∼80 percent of the proteins are N-terminally
acetylated, which blocks Edman sequencing
[6].Incontrast,N-terminalacetylationrarely
occursinprokaryoticproteinsandeukaryotic
proteins expressed in bacteria.
Peptide Synthesis Resource:
Small Scale
Small-scale Fmoc peptide synthesis is
used by this Resource to synthesize > 1,000
custom peptides annually and is generally
suitable for seven to 30 residue peptides.
Since the degree of difficulty in synthesizing
peptides is length, composition, and se-
quence dependent, some peptides within this
range will prove to be difficult to synthesize.
Conversely, many peptides longer than 30
residues can be synthesized.Awide range of
modified amino acids may be incorporated
into small-scale synthetic peptides, with the
primary limitation being the commercial
availability of the required Fmoc derivative.
Synthesized peptides are confirmed by mass
spectrometry (MS) to have the expected
MW and are accompanied by an analytical
RP-HPLC profile.
Peptide Synthesis Resource:
Large Scale
Synthetic peptides routinely are made
up to 40 residues and often, depending on
their sequence, up to 70 residues. Peptides
that can be purified are chromatographed by
RP-HPLC and then are delivered as a
lyophilized material. Yields for “normal”
peptides (which are made at the 0.5 mmole
scale with tBOC chemistry) under 40
residues are > 50 mg at + 90 percent purity.
For the incorporation of unusual amino
acids, such as non-radioactive isotopes, the
appropriate tBOC and side-chain protected
material must be supplied by the submitter at
a level of 2 mmoles/residue. The presence
of the synthesized peptide with the expected
mass is confirmed by MS.
EMERGING PROTEOMICS
TECHNOLOGIES
Mass Spectrometry and Proteomics
Resource
A broad spectrum of MS based tech-
niques, HPLC, and chemistries are used to
separate, characterize, and quantify analytes
from complex biological samples. The 11
staff members include four PhD-level ap-
pointments with > 100 years of MS and pro-
tein chemistry experience. This Resource
has nine state-of-the-art tandem mass spec-
trometer systems, including TOF-TOF,
Quadrupole-TOF, Triple-Quadrupole, FT-
ICR, and LTQ-Orbitrap type analyzers with
either matrix assisted laser desorption ion-
ization (MALDI) or electrospray ionization
(ESI) sources coupled to HPLCs (Table 2).
MS samples include proteins, oligonu-
cleotides, lipids, carbohydrates, synthetic
peptides, and many small molecules. In
2006, for example, 14,077 MS analyses
were completed for 24Yale departments and
86 outside institutions.
To address the rapidly increasing inter-
est, this Resource offers nine proteome pro-
filing technologies (Table 3). The methods
depend upon either protein or tryptic peptide
separation and quantitation. Protein separa-
tions use either differential 2D gel elec-
199 Williams: Keck Labtrophoresis (DIGE) with MALDI-MS/MS
identification of tryptic digests of proteins in
spots of interest or automated 2D HPLC.
While fluorescence labeling allows DIGE to
analyze up to three proteins in the same gel,
2D HPLC analyzes one protein extract per
analysis with quantitation based on the A210
nm absorbance of the RP-HPLC second di-
mension. The remaining seven technologies
(Table 3) involve analysis of tryptic or other
digests of protein extracts. These “bottom-
up”approachesrelyontandemmassspectral
peptideidentificationandcanbequantitative
with chemical or stable-isotope tagging of
proteinsorpeptides(e.g.,iTRAQ).Theweb-
based YPED platform transmits profiling
datatousersandalsoarchivesthedataandis
being equipped with tools to integrate, ana-
lyze,andvisualizetheresults.Twonewtech-
nologies are phosphoproteome profiling and
quantitative analysis of pre-selected, poten-
tial biomarker proteins. We also are launch-
ing a label-free quantitation technology for
disease biomarker discovery using FT-ICR
LC-MS to analyze trypsin digests of com-
plex cell and tissue extracts.
ESTABLISHED GENOMICS
TECHNOLOGIES
Conventional DNA Sequencing
Four technologies are provided: single
tube and high-volume, 96-well plate DNA
Sequencing; fragment analysis; and primer
walking. A Tecan Genesis workstation
aliquots reagents and samples, while a Bio-
mek NX system carries out post-cycle se-
quencing cleanup via Agencourt’s
CleanSEQ methods. We plan to implement
new services that would allow researchers
to submit samples in 384 well format or in
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Table 3: Overview of Proteome Profiling Technologies Available from the Keck Laboratory MS and
Proteomics Resource at Yale University
Technology
MudPIT [7]
ICAT
iTRAQ
SILAC
DIGE [12, 13]
PF2D Automated 2D
Protein Fractionation
Label Free Quantitation
[1]
MRM based Targeted
proteomics
Phospho-proteomics
Requires Labeling?
No
C12/C13 cleavable ICAT
reagent at Cys
Isobaric tags at
N-terminus & epsilon-N of
Lys of peptides
Stable isotope labeled
peptides
In vitro with Cy fluoro-phores
at primary amines OR
at cysteines
No
No, see [16]
stable isotope labeled pep-
tides
No
Detect PTM's
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Max. #
Proteins
Detected
872 [8]
491 [9]
685 [10]
5,111 [11]
1500-2000+
[14]
2,500 [15]
N/A
100 [17]
2,328 [18]
Comments
2D LC approach used to catalogue
proteins from complex samples
2-plex; only detects Cys-containing
proteins, cannot generally detect
protein post-translational modifica-
tions
4-plex & 8plex MS/MS quantitation
based on intensity of 114 -117 re-
porter ions
Protein samples are mixed after cell
harvest; any number of MS based
fractionation steps can be used with
minimal quantitation error
3 samples compared in same gel;
very useful for protein isoform de-
tection
Uses 2D Chromato-focusing/ and
reversed phase HPLC to quantify
pairwise RP fractions by UV
LC-MS based disease biomarker
discovery tool; follow up required
for protein ID
Means for Absolute Quantitation; in-
ternal peptide standards are syn-
thesized or made via ICAT or
iTRAQ
Enrichment step is required; phos-
phorylation sites are determined;
label & label-free techniques are
used for quantitationfour 96 well plates to have them combined
into a 384 well plate. Use of the 384 well
plate would reduce reaction volumes from
10 ﾵl to 5 ﾵl, which would reduce reagent
costs and lower service charges. We also
would hope to offer PCR product cleanup
for researchers submitting PCR samples in
high volume plates.
Oligonucleotide Synthesis
Nucleic acid syntheses use beta-cya-
noethyl chemistry on 13 instruments (Table
2). Oligo synthesis is offered at three DNA
scales (50, 200, and 1,000 nmol) with
lengths up to 250-mers and a wide range of
synthesis services, including derivatized
DNA oligos containing a large variety of
structures; RNAand 2’-O-methyl RNAand
chimers of these and DNA, plus derivatives
as above; phosphorothioation; and gel pu-
rification of DNAoligos. New modifications
are offered as they become available, and
procedures are optimized for each. DNAoli-
gos are delivered fully deprotected,
lyophilized, and unpurified with hydroxyl
groups at both ends. Exceptions are:
• Trityl-On oligos are supplied on the
support without cleavage or deprotection;
• RNA oligos are delivered with a 2’-
protecting group to prevent degradation;
•ModifiedoligosrequiringUltraMildde-
protection (i.e.TAMRA-dT, etheno-dA, cy3,
cy5etc)aresuppliedcleavedanddeprotected
in 3 mls potassium carbonate/MeOH/TEAA
and must be desalted before use.
The quality of unpurified products is
maximized by using high quality reagents
and optimizing synthesizer cycles. Oligo
syntheses are monitored by trityl yields and
by analyzing about 20 percent of oligos by
201 Williams: Keck Lab
Figure 1. Image of an Illumina 1,500 cus-
tom SNP panel.
Table 4: Overview of Keck Technologies Available to Study Genetic Events
Genetic Events
Genetic Susceptibility
Somatic and germ line mutations
Gene amplification and deletions
Epigenetic modifications
Differential gene expression
Alternative splicing
Gene regulation
SNP discovery
miRNA discovery
miRNAAnalysis
Sequencing and resequencing
Common Detection Methods
Linkage and Association
SNP identification and genotyping
Comparative genome amplification analysis
Gene and Exon-level amplification analysis
Methylation, PCR/bisulfite sequencing, ChIP
Gene and Exon-level analysis
Exon level analysis
ChIP
Direct sequencing
Direct sequencing
Microarray and sequence analysis
Direct sequencing
Applicable technology/platforms
Affymetrix, Illumina, Sequenom, Nimblegen
and Solexa
Affymetrix, Illumina, Sequenom, Nimblegen
and Solexa
Affymetrix, Illumina, Sequenom, Nimblegen
and Solexa
Affymetrix, Illumina, Sequenom, Nimblegen
and Solexa
Illumina, Sequenom, Nimblegen, Solexa
and Affymetrix (tiling array)
Affymetrix, Illumina, Sequenom, Nimblegen
and Solexa
Affymetrix
Affymetrix, Nimblegen, Solexa
Solexa
Solexa
Solexa
Exiqon miRCURY arrays, Illumina and
Solexa
Solexacapillary electrophoresis. The quality of our
unpurified oligos is sufficiently high that
they usually are used directly (or after de-
salting) for sequencing or PCR. Although
the website provides anticipated DNA
yields/base, we urge users to determine oligo
DNA concentrations before use. For se-
quences > 100 bases, we recommend 200
nanomole or 1.0 ﾵmole scales. The turn-
around time for normal DNAoligos is typi-
cally < 24 hours for < 60-mers.
EMERGING GENOMICS
TECHNOLOGIES
Microarray Resource
Thisfull-serviceResource(Tables1and
4) is dedicated to providing RNAexpression
profiling, DNA genotyping (Figure 1), high
throughput DNA sequencing, and mi-
croRNAanalysisservices usingAffymetrix ,
Illumina, NimbleGen, Solexa, Sequenom,
and Applied Biosystems 7900 instrumenta-
tion, as well as in house spotted arrays. A
supplement to the Yale Cancer Center NCI
Core Grant helped fund the instrumentation
needed to initiate the spotted glass section of
the Microarray Resource in 1999. The
Affymetrixplatformwasestablishedin2001
to support carrying out large-scale gene ex-
pression studies utilizing commercially
available microarrays. The Microarray Re-
source has 10 staff and occupies 5,350
squarefeetonthesecondfloorat300George
Street and contains Class 100 clean rooms
for printing and slide processing. From July
2004 to June 2007, this Resource provided
about 18,000 services to 537 researchers
from Yale and 313 from 160 other institu-
tions. To our knowledge, there have been
about 140 publications utilizing its services.
It has emerged as one of the leaders in the
identification of disease-causing genetic fac-
tors as evidenced by recent publications in
Science identifying genes associated with
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Figure 2. DNA induced dimerization of FIR-protein. Oligomeric State of FIR alone and of
the FIR-DNAcomplex from SEC-UV/LS/RI analysis. Weight average molecular weights de-
termined from SEC-UV/LS/RI analyses are plotted as filled triangles for FIR-DNA complex
and open triangles for FIR protein alone. Averages and standard deviations were calculated
from 25 MW determinations for the top 0.2 ml of the eluting peaks for which the concentration
is within 5 percent of the plotted value.age-related macular degeneration [19] and
coronary disease and metabolic risk factors
[20]. In addition to the NIH Center and High
End instrumentation grants mentioned
below,thisResourcealsoobtainedanadmin-
istrative supplement that partially funded its
Illumina microarray system.
SUPPORTING BOTH GENOMICS
AND PROTEOMICS
Biophysics Resource
This Resource provides technologies
thatallowcharacterizationofinteractionsbe-
tween biomolecules, including the
oligomeric state of the interacting species,
thermodynamic parameters that govern the
interactions including binding constants, the
enthalpic and entropic contributions to com-
plex formation, and kinetic information: kon
and koff rates. The instrumentation in the re-
source (Table 2) allows determination of the
oligomeric state of the interacting species
and of the resulting complex utilizing size
exclusionchromatography/laserlightscatter-
ing (SEC/LS) or dynamic laser light scatter-
ing (DLS). As illustrated in Figure 2 for a
DNA-bindingdependentdimerizationofFIR
protein [21], binding constants are deter-
mined using isothermal calorimetry (ITC),
surface plasmon resonance (SPR), or an
SLM 8000C spectrofluorometer; kinetics
using stopped-flow and SPR; and the en-
thalpyandentropyofbindingreactionsusing
ITC—whichisanalmostuniversaltechnol-
ogy for studying macromolecular interac-
tions that is based on the heat that
interactionsgiveoffortakeupuponcomplex
formation. Thus, this approach does not re-
quirelabelingoftheinteractingspecies.Sim-
ilarly, (SPR) also is used to study label-free
macromolecular interactions. SPR detects
binding in real time by monitoring changes
inmassconcentration atthe chip surface;the
association and dissociation rate constants
are determined from the reaction traces.
Samples ranging from small molecules to
crude extracts, lipid vesicles, viruses, bacte-
ria,andeukaryoticcellscanbestudiedinreal
time with little or no sample preparation.
The best methods for each project are
recommended based on the questions being
addressed, the amount of available sample,
and the spectroscopic properties of the inter-
acting molecules. Samples are accepted for
analysis on a “fee-for-service basis” or
through “open access,” whereby investiga-
tors havedirectuse of theneeded instrumen-
tation. The resource provides instrument
training and support for each project’s de-
sign, execution, and interpretation of the re-
sulting data. This approach allows
investigators with little knowledge of bio-
physics to successfully complete advanced
biophysicalanalysesthathavebeendesigned
to best address their research challenges.
A new NIH SIG will fund Asymmetric
Flow Field-Flow Fractionation (AFFF) and
Automated Composition Gradient (CG) sy-
ringe delivery systems that will share Light
Scattering (LS) and other detectors.AFFF is
a single phase chromatography technique
that can separate samples from 1nm to > 20
microns. High-resolution separation by size
is achieved within a very thin channel
against a perpendicular flow force. The en-
tire separation is gentle, rapid, and non-dis-
ruptive — without a stationary phase that
may degrade, bind, or otherwise alter the
sample. The combination ofAFFF fraction-
ation and light scattering (LS) detection al-
lows sample fractionation and determination
of size and molar mass in a single experi-
ment. The coupling of the LS measurement
to a fractionation step provides the ability to
determine the molar masses and oligomeric
states of very diverse macromolecules (e.g.,
proteins and their complexes, nucleic acids,
liposomes, and polysaccharides). In contrast
to ultracentrifugation, fractionation and siz-
ing onAFFF/LS allows the facile collection
of fractions for further analyses.
Biostatistics Resource
This Resource provides state-of-the-art
statisticaldataanalysisofgenomics,genetics,
and proteomics research using open source,
commercialsoftware,andin-houseprograms.
The Biostatistics Resource has collaborated
with the Keck Microarray and Proteomics
Resources and the Center for Medical Infor-
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Yale Microarray Database (YMD) and Yale
Protein Expression Database (YPED). The
Biostatistics Resource also collaborates with
the Yale Center for Statistical Genomics and
Proteomics to develop pathway and protein
interaction database and visualization tools
and collaborates with and complements the
BioinformaticsResource.Finally,theBiosta-
tistics Resource works with the High Per-
formance Computing (HPC) Resource on
those challenges amenable to an HPC solu-
tion. While fee-based services are provided
for well-defined projects, this Resource also
is involved in biostatistical research and de-
veloping novel statistical methods to analyze
gene expression data [2] and genetic associ-
ation and proteomics data [3,4]. Where suc-
cess requires deeper scientific involvement,
the Biostatistics Resource will work collabo-
ratively. In fiscal year 2007, the Biostatistics
Resource carried out 61 services for 25 Yale
usersfrom14departmentsandcentersaswell
as 26 services for 15 users at 14 non-Yale in-
stitutions. The Biostatistics Resource cur-
rently has research collaborations with Drs.
JudyCho(InternalMedicine),JoelGelernter
(Psychiatry), and Zoran Zimolo (Psychiatry)
at Yale University and also with groups of
non-YaleinvestigatorsatIntrinsicBioprobes,
Inc.
Bioinformatics Resource
This Resource’s mission is to provide
bioinformatics support at three levels. First,
freeorsubscription-based24/7accessispro-
vided to many commercial and open source
bioinformatics programs. Some software is
loaded on Resource PCs, while other soft-
ware can be used remotely, either through
client programs or with aWeb browser. Soft-
wareprovidedbytheResourceareloadedon
Windows and Linux workstations available
24/7intheResource;afewprogramsaresub-
scription,Web-basedservicesaccessiblewith
aWebbrowser;andsomeareremotelyacces-
sible after installation of a client program on
the user’s PC. The available software covers
awiderangeofapplications,includinganaly-
sisofDNA/proteinsequences,microarrayex-
pression and genotyping data, pathway and
network analysis, protein structure modeling
and docking (Figure 3). Bioinformatics staff
will recommend the most appropriate soft-
ware to meet individual research objectives
and provide training in the use of these re-
sources. Second, the staff will provide fee-
based consultation services for well-defined
bioinformatics analyses. Third, the staff will
collaborate on projects requiring a longer
commitment of time and effort, which often
will be charged to an appropriate grant.
The Bioinformatics Resource should
verypositivelyleveragethevalueofthetech-
nologies provided by the Biostatistics and
several other Keck Resources, including Mi-
croarray,MS/Proteomics,andDNAandPro-
tein Sequencing. Finally, the clusters and
other instrumentation in theYale Biomedical
High Performance Computing (HPC) Center
and the computer scientists in the HPC Re-
source work with the Bioinformatics Re-
sourceontasksamenabletoanHPCsolution.
High Performance Computing
(HPC) Resource
The HPC Resource plays a critical role
in the newYale University Biomedical Cen-
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Figure 3. Molecular model for
DEF site-MAPK interactions.
Docking of a capped pentapeptide
ligand representing the DEF se-
quence (acetyl-SFQFP-amide) to
the active form of ERK2 was mod-
eled using AutoDock. This is a
joint research project involving Dr.
Y. Kong of the Bioinformatics Re-
source with Dr. B.Turk and Dr. D.
Sheridan of the Department of
Pharmacology, Yale University.ter for High Performance Computing (see
below).The HPC Resource is co-directed by
two Ph.D.-level computer scientists. To-
gether, they provide the parallel program-
ming knowledge for bringing HPC to bear
on research. The interaction between users
and the Resource varies widely, depending
upon the interest and ability of each user. In
some cases, experienced investigators are
provided with accounts and proceed on their
own. Usually, however, the HPC center’s
staff consult with users to some degree.Typ-
ically, one of the center’s computer scientists
examines and benchmarks user’s codes,
often finding ways to improve the serial per-
formance or to parallelize the code or both.
EVOLUTION OF CHALLENGES AND
GENERAL OPERATING POLICIES
Charging for services
To avoid having its financial stability
depend completely upon grants, the Keck
Lab adopted a different model in which user
fees play a major role. In 1980, the idea of
each user paying for the actual cost of car-
rying out its biotechnology analyses and
syntheses was quite counter to the prevail-
ing mechanism of obtaining access to ex-
pensive biotechnology analyses and
syntheses by collaborating with faculty who
had the needed instrumentation. Williams
encountered such strong opposition to
charging for the cost of carrying out
biotechnology services that he was one of
the six founders of the Association of
Biotechnology Resource Laboratories
(ABRF, http://www.abrf.org/). Soon after its
incorporation in 1988, theABRF carried out
a survey of core laboratories [5]. A signifi-
cant finding was that the extent of subsi-
dization of core lab operating expenses
varied over a wide range. This makes it
quite misleading to simply compare web-
posted service charges at different core lab-
oratories. The ABRF continues to play a
valuable role as “an international society
dedicated to advancing core and research
biotechnology laboratories through re-
search, communication, and education.”
Expansion creates a continuing
financial challenge
The expansion of the Keck Laboratory
from 1980 to 2008 created a continuing fi-
nancial challenge. While several factors
enter into the Keck Laboratory’s decisions
about which new technologies to provide —
with the potential positive impact on re-
search being paramount — one guideline is
to focus on services requiring instrumenta-
tion that is too expensive to be purchased by
individual research laboratories and requires
a high level of expertise and large number
of samples/requests to keep the instrumen-
tation operating at its maximum capabilities.
Our experience shows that most instruments
— especially those with fluidics and valves
— have the lowest malfunction rate when
operated continuously. The latter is difficult
for a single research laboratory to achieve
— where demand for individual technolo-
gies tends to ebb and flow. Since the Keck
Lab provides technologies to hundreds of
Yale and non-Yale laboratories at hundreds
of institutions, it is often able to maintain a
backlog of non-Yale requests that it utilizes
during those times when demand byYale in-
vestigators is below average. A major chal-
lenge created by continuing expansion of the
Keck Lab is that the purchase value of its in-
strumentation is now about $17 million.As-
suming an average instrument life span of
seven years requires that the Keck Lab ob-
tain $2.4 million dollars annually just to re-
place obsolete and worn-out equipment —
and that does not include purchasing equip-
ment needed to expand to meet increasing
demand for existing technologies nor to pro-
vide new technologies.
An important source of instrument
funding for the Keck Lab has been the an-
nual NIH Shared Instrumentation Grant
(SIG) program, which funds instrument sys-
tems in the $100,000 to $500,000 range, and
a “High End” variant of this program that
funds instruments in the $1 to $2 million
dollar range. However, even if the Keck Lab
were able to obtain a “standard” SIG each
year, this would provide only 20 percent of
the $2.4 million dollars per year needed to
sustain existing biotechnologies. Since 1981,
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SIG applications with 21 (84 percent) being
funded.Among them have been three “High
End” awards that funded an FT-ICR MS,
most of the instrumentation in the Biomed-
ical High Performance Computing Center,
and “next generation” DNA sequencing
equipment, including a Solexa instrument.
Taken together, the 21 grants have covered
about 48 percent of the purchase cost of in-
struments that are “online” in the Keck Lab.
Other sources have included institutional
funds and user fees.
Advantages of providing support
for instrumentation in core laboratories
The institutionaladvantages of having a
well-equippedbiotechnologycorelaboratory
are numerous.Although impossible to quan-
tify, we believe state-of-the-art biotechnol-
ogy support from core laboratories leads to
increasedresearchproductivity,publications,
grant funding, and indirect costs for the in-
stitution. Additionally, “cutting edge” core
laboratories can enhance recruitment and re-
tentionoftheverybestfaculty,researchstaff,
and students. Core laboratories also provide
access to well-trained staff, who typically
have many years of expertise with a wide
range of sample types/requests. By contrast,
research laboratory staff may not have the
knowledge and experience needed to opti-
mally prepare samples for a given technol-
ogy while also minimizing sample loss; may
not have the advantages gained from having
attended training courses given by manufac-
turersofbiotechnologyinstrumentation;may
lack the experience needed to operate ad-
vancedinstrumentationatthelimitsofitsca-
pability;andmayfailtoquicklydetectsubtle
indicators of impending malfunctions of in-
strumentation. In comparison to the approx-
imate $436,200 cost of equipping each
laboratory in a university that needs access
toaquantitativeproteinprofilingtechnology
such as Multiplexed Isobaric Tagging Tech-
nology (iTRAQ™), it is less expensive for
universities to equip a core laboratory with
theinstrumentationneededtobringthistech-
nologywithinequalreachofallinterestedin-
vestigators. Although there are some
instances in which it is worthwhile to equip
an individual laboratory with expensive
biotechnology instrumentation (e.g., if they
wish to devote considerable instrument time
to teaching — perhaps by integrating it into
laboratory courses, are carrying out research
on the instrumentation itself, have unusually
large and continuing demand for the instru-
ment funded by multiple grants, or have spe-
cialized requirements unique to their
laboratory that require significant modifica-
tions of the instrument), most often we be-
lievethisoptionisnotbestfortheinstitution.
Commercial vs. institutional core
laboratories
TheKeckLabissometimesaskedwhyit
offers technologies such as “conventional”
DNAsequencingandoligonucleotidesynthe-
sis, which are offered at lower fees by some
commercial laboratories. The simple answer
goes back to the foundation upon which the
Keck Lab was built: to meet the needs of the
Yalescientificcommunity.Overthelastseven
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Figure 4. “Conventional” DNA sequencing
reactions carried out from fiscal year 2001-
2007 by the Keck DNA Sequencing Re-
source. The Yale University fiscal year
extends from July 1 through June 30.years, the demand for DNA sequencing has
increased about 18 percent annually (Figure
4). In fiscal year 2007, the Keck Lab carried
out 204,024 DNA sequencing analyses with
>88percentoftherequestscomingfrom376
Yale investigators. It seems likely that the in-
creasing demand for this Keck service results
from faster turnaround, higher quality data,
higher success rate, more personalized serv-
ice,moreresponsivestaff,andmoreextensive
assistance with analysis of multiple datasets,
comparedwiththeservicesprovidedbycom-
mercial DNA sequencing companies. Simi-
larly, in fiscal year 2007, the Keck Lab
synthesized 32,051 custom oligonucleotides,
with > 86 percent of these requests coming
fromYale,whichrepresenteda10percentin-
creasefrom2006.Byusingthreeoverlapping
staffshifts,thisKeckResourceusuallyisable
to provide < 24 hour turnaround for unpuri-
fied, 40 nanomole DNAoligos that are < 60-
mers. Another factor contributing to the
increased use may be the very broad range of
modified oligonucleotides (many of which
maynotbeavailablecommercially)thathave
been synthesized successfully by this Re-
source. In the case of state-of-the-art biotech-
nologies, such as the phosphoproteome
profiling technology recently introduced by
the Keck MS/proteomics Resource, we have
not been able to find any commercial vendor
thatprovidesacomparabletechnology.Other
biotechnologies(e.g.,theSEC/laserlightscat-
tering technology from the Biophysics Re-
source) appear to be more expensive from
commercialvendorsthanfromtheKeckLab.
Key operating policies
To maximize its positive impact on re-
search, the Keck Lab strives to provide as
many high-quality services to as many inves-
tigators as possible.Although priority always
is given to Yale investigators, accepting re-
quests from scientists from across the United
States and around the world helps ensure the
backlogrequiredtomaintainhighproductivity.
This policy, which benefits all users, mini-
mizesoperatingcostsbyincreasingproductiv-
ity, maximizes the contribution of the Keck
Lab andYale University to research, and also
contributestothehighsuccessratethelabhas
had at obtaining SIGs. Virtually every Study
SectionreviewofaKeckSIGapplicationcon-
tains statements such as: “The Keck Founda-
tion Biotechnology Resource Laboratory at
Yale University is the premier biotechnology
resourcecenterintheworldandisamodelfor
suchfacilitiesonascalethatmostuniversities
cannot even contemplate. The contribution of
this lab to biomedical research in the U.S. has
been and will continue to be enormous. They
are a role model for how a core lab should
work.” In keeping with this philosophy, most
analyses and syntheses are provided as serv-
ices,sinceitwouldnotbefeasiblefortheKeck
Labtocollaboratewithevenasmallfractionof
the 993 investigators from 280 institutions in
22 countries who utilized 255,559 Keck serv-
ices in fiscal year 2007. Whether services are
carried out on a service or collaborative basis,
however,eachYaleuserisgiventhesamefirst-
come,first-servedpriorityandturnaround.Un-
less an instrument malfunctions or the sample
is being used to test or optimize a new proce-
dure, the cost of carrying out each service is
charged either to a user or a Keck grant.
Space: The Ultimate Challenge
The Keck Lab received its current name
in1989,whenYalewasawardedagrantfrom
the W.M. Keck Foundation to build 3,350
square feet of customized biotechnology
spaceintheBoyerCenterforMolecularMed-
icine.Thevolumeofservicescontinuedtoin-
crease, and over the next decade, the Keck
Lab was forced to borrow additional space
from departments scattered throughout the
School of Medicine. By 2001, it had become
clear that the Keck Lab needed a new home,
andtheSchoolofMedicinerenovatedanother
approximate25,000squarefeetofcustom-de-
signed laboratory and support space at 300
George Street — space that now houses 50
Keckstaffandabout100instrumentsystems.
FUNDING OF THE KECK LAB
Important role for center grants
The value of the Keck Laboratory’s in-
strumentation has been very positively
leveraged by the awarding of several center
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biotechnological research and subsidized ac-
cess for center investigators to new tech-
nologies.As new and improved technologies
and databases are developed by these cen-
ters, they are rapidly published, offered as
services, and made available to users of the
Keck Lab. Examples include implementa-
tion and development of many new protein
profiling technologies (see above) and two
major institutional databases built in collab-
oration with theYale Center for Medical In-
formatics:
•Yale Microarray Database:YMD is an
Oracle database that archives microarray
data and provides tools to retrieve and ana-
lyze spotted microarray data. We are in the
process of archiving data intoYMD that has
been generated by theAffymetrix GeneChip
microarray platform.
• Yale Protein Expression Database
(YPED): YPED is an interoperable protein
expression database being built to archive,
manage, and analyze the very large data sets
generated by Keck, other proteomics cen-
ters, and investigators to quantify the rela-
tive levels of expression of thousands of
proteins in hundreds of samples annually.
The Keck Lab contains or is very
closely associated with several NIH Centers:
•Yale/NHLBI Proteomics Center is one
of 10 centers established in 2002. This cen-
ter supports 19 projects that use
protein/phosphoprotein profiling and the de-
velopment of cell-permeable, synthetic
biotechnologies for blocking specific pro-
tein:protein and protein post-translational
modifications in vivo.
• Northeast Biodefense Center (NBC)
is one of 10 Regional Centers of Excellence
established in 2003. The NBC Proteomics
Core encompasses six Keck proteomics re-
sources and supports basic and clinical
biodefense research programs.
• Yale/NIDA Neuroproteomics Re-
search Center is one of two centers estab-
lished in 2004 that brings together 14 Yale
research programs in proteomics and signal
transduction in the brain with MS/Pro-
teomics Resource and other Keck staff to
identify adaptive changes in protein signal-
ing that occur in response to substance
abuse.
• The instrumentation in the Yale Bio-
medical Center for High Performance Com-
puting (HPC) was funded primarily by a
2004 NIH Instrumentation Grant. Yale ITS
provides systems administration and com-
puter scientists in the Keck HPC Resource
work with researchers to optimize codes, de-
velop parallel variants, explore new formu-
lations, and support new genomic (e.g.,
Solexa DNA sequencing) and proteomic
technologies as they are brought online by
the Keck and other laboratories. Seventy-
nine users from 33 laboratories logged 2.25
million CPU-hrs on this center’s clusters in
2007.
• The Yale Microarray Center for Re-
search on the Nervous System was estab-
lished in 2005 as one of four centers to
provide DNA microarray services at lower
cost to approximately 10,000 neuroscientists
funded by 15 NIH Blueprint Institutes, thus
supporting a broad range of research, and is
located primarily within the Keck Lab.
• Yale Cancer Center (YCC) shares the
Keck Proteomics/Biophysics and Microar-
ray Resources, both of which were rated as
outstanding during the 2007 review of the
successful YCC competing grant renewal.
TRAINING, EDUCATION AND
COMMUNITY SERVICE
The Keck Lab views education and
training of users and theYale community as
one of its most important functions.This ed-
ucation includes training workshops, indi-
vidual training, user groups, seminars,
Web-based training, newsletters, and publi-
cations.To help users take maximum advan-
tage of its resources, the Keck Web pages
provide information on the biotechnologies
it offers and on interpreting the resulting
data. Keck staff have trained core laboratory
staff from as far away as Argentina and
South Korea. Since 2004, Keck staff have
presented many posters and have given
about 20 seminars at Yale and 18 invited
talks at scientific meetings. Responding to
the need for more minorities in scientific re-
208 Williams: Keck Labsearch, the MS/Proteomics Resource spon-
sored two minority undergraduate students
for a 10-week summer research and science
mentorship program funded by Yale
BioSTEP. Multiple Keck staff have served
as judges in New Haven’s annual high
school science fair and offered science edu-
cation presentations and Keck Laboratory
tours for local middle school science stu-
dents and teachers. Keck Resource directors
and staff periodically visit and teach after
school science classes to area elementary
school students. In 2006, Shrikant Mane,
PhD, provided hands-on training for
GeneChip expression analysis to a Hamden
High School science teacher. Similarly, Dr.
Tukiet Lam provided scientific outreach to
20 Albertus Magnus College students and
teachers by demonstrating FT-ICR MS in-
strumentation and technologies.The dedica-
tion of the Keck Lab to education was
mentioned in the summary statement from
one of our current NIH SIG awards
(RR024617): “The laboratory and staff are
also committed to graduate, undergraduate,
and high school level educations and it is
clear that the availability of an (LTQ-Orbi-
trap) ‘CSI’-type instrument may encourage
students to pursue a career in science.”And
lastly, the Biostatistics Resource has en-
gaged in many education and training activ-
ities that included Dr. Zhao organizing the
Genome-wide Association Conference
(2006) that was well attended.
CONCLUSIONS
The genomics “revolution” has suc-
ceeded in sequencing the human and many
other genomes and was made possible by
key discoveries in molecular biology (e.g.,
restriction enzymes) and the amazing rate at
which major biotechnological break-
throughs were and are continuing to be
made in this broad field.As anticipated, the
ever-growing knowledge about the human
and other genomes as well as the new and
very powerful genomics biotechnologies are
giving rise to impressive achievements that
span from taxonomy to criminal investiga-
tions to uncovering genes associated with
human disease. Realizing the importance of
spurring a similar revolution in proteomics,
NIH has funded biotechnology centers and
grants to develop more powerful proteomics
technologies. Generally, however, the ex-
pectations for proteomics have exceeded the
clinical accomplishments. Some of the driv-
ing forces for a proteomics “revolution” are
the renewed appreciation that the biological
effector molecule generally is the protein
and not its encoding mRNA; the inability of
predicting the occurrence of many important
protein post-translational modifications
(PTM) such as phosphorylation (which is
thought to occur on as many as one-third of
human proteins and often plays a key role in
modulating protein function) from genomics
data; and the frequent lack of agreement be-
tween mRNA vs. protein expression data
(e.g., see [22]).
Several challenges stand in the way of a
true proteomics “revolution,” and they are
illustrated in human plasma, which is the
most complex human proteome but also the
most useful as it potentially contains virtu-
ally the entire human proteome due to tissue
“leakage” and is the most readily available
clinical specimen. While there are probably
only a relatively modest number of true
plasma proteins (e.g., about 500 secreted by
the liver and intestines), each is present in
an average of perhaps 100 forms due to dif-
ferential glycosylation, splicing, proteolytic
processing, and PTMs [23]. Added to these
50,000 protein variants are perhaps almost
21,000 other human proteins [24] that may
leak into the plasma and may each be pres-
ent in about 50 variant forms (e.g., five re-
sulting from alternative splicing/promoter
usage and 10 from the addition of > 200 dif-
ferent PTMs), thus adding another
1,000,000 potential “plasma” proteins that
are then mixed with perhaps another 10 mil-
lion different immunoglobulin sequences
[23]. Adding considerably to the challenge
is the 10 order of magnitude range in protein
concentrations in plasma, which is many or-
ders of magnitude above the dynamic range
of any current biotechnology such as
iTRAQ, DIGE, or immunological platforms.
Three approaches used to try to address the
209 Williams: Keck Labwide dynamic range of individual plasma
proteins are depletion of abundant proteins
such as serum albumin, enrichment (by im-
munological or other means) of classes of
proteins of interest (e.g., phosphoproteins),
and multi-dimensional/multistep approaches
used to fractionate plasma prior to proteomic
analysis. One need not look very far into the
Keck Web pages to discern that while ge-
nomics can interrogate the relative level of
expression of approximately 38,000 human
transcripts on a single array and a single chip
can analyze 1 million human SNPs, pro-
teomics is limited to the range of about 500
to 700 (with optimal iTRAQ samples) to
1,000 to 2,000 proteins/sample (with opti-
mal DIGE samples). We believe that to
reach the expectations anticipated for pro-
teomics, this several order of magnitude dif-
ference between the capabilities of
contemporary genomic and proteomics tech-
nologies must be closed, and currently, it is
not clear if any of the available proteomics
technologies have the inherent capability to
do so. While we believe that closing this
biotechnological gap is one of the most dif-
ficult of all biotechnological challenges, we
also believe the rewards for doing so will
prove to be well worth the needed effort and
funding. In our opinion, however, no gov-
ernment agency has yet made the high level
of sustained commitment that will be needed
to bring the goal of “routine” interrogation
of the human proteome within reach.
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